Randomized controlled trialHuman

Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension

Journal of acquired immune deficiency syndromes (1999), 2010 Mar. Falutz J, Potvin D, Mamputu JC and 10 others.

Study type

Randomized controlled trial

Subjects

Human participants (PubMed MeSH: Humans)

Journal

Journal of acquired immune deficiency syndromes (1999)

Published

2010 Mar

PubMed

PMID 20101189 ↗

DOI

10.1097/QAI.0b013e3181cbdaff ↗

Where PepCue cites this

This paper is part of the evidence base behind this profile. Citing a study is not an endorsement of the compound: papers that found no effect are indexed the same way.

Tesamorelin →gh secretagogues compared →tesamorelin only fda approved gh peptide →

Indexed under

MeSH terms assigned by the National Library of Medicine.

Abdominal FatAdultAnti-HIV AgentsDouble-Blind MethodFemaleGrowth Hormone-Releasing HormoneHIV InfectionsHIV-Associated Lipodystrophy SyndromeHumansIntra-Abdominal FatMaleMiddle Aged

Other papers on Tesamorelin

Randomized controlled trial · 2019

Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial

Randomized controlled trial · 2014

Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial

PepCue indexes citation metadata only and does not reproduce abstracts or full text. Read the paper at the source links above. Nothing here is medical advice or a dose recommendation.

Educational and research reference only. Not medical advice, diagnosis, or dosing guidance. Flag an error on this page